ArticleCEN case reports2021
Nephrotic syndrome relapse in a boy with COVID-19.
Article in CEN case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- COVID-19 and idiopathic nephrotic syndrome in children: systematic review of the literature and recommendations from a highly affected area.Pediatric nephrology (Berlin, Germany) · 2022Pooled it
- Serum IL-38 and the rs7599662 polymorphism: novel biomarkers for pediatric idiopathic nephrotic syndrome.Italian journal of pediatrics · 2026Article
- Extending the concept of 'exhausted T-cells' to idiopathic nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2026Article
- Coronavirus Disease 2019-associated Minimal Change Disease: Transient Improvement Does Not Preclude the Need for Standard Therapy in a Case Report and Review of the Literature.Internal medicine (Tokyo, Japan) · 2026Review
- Increased Measured GFR and Proteinuria in Children with Previous Infection by SARS-CoV-2: Should We Be Concerned?Microorganisms · 2025Article
- Nephrotic syndrome: pathophysiology and consequences.Journal of nephrology · 2023Review
- Relapse rate in children with nephrotic syndrome during the SARS-CoV-2 pandemic.Pediatric nephrology (Berlin, Germany) · 2023Article
- Child with new onset nephrotic syndrome as the sole manifestation of SARS-CoV-2 infection.Journal of paediatrics and child health · 2022Article
- New-onset immunoglobulin-A nephropathy post severe acute respiratory syndrome-coronavirus-2 infection indicates rapidly progressive glomerulonephritis.Nephrology (Carlton, Vic.) · 2022Article
- Can microalbuminuria be an ındicator of renal ınvolvement in pediatric Covid 19 patients?Infection · 2022Article
- Adult-onset nephrotic syndrome following coronavirus disease vaccination.Clinical kidney journal · 2022Article
- Intrinsic Kidney Pathology Following COVID-19 Infection in Children and Adolescents: A Systematic Review.Children (Basel, Switzerland) · 2021Review
- The role of the immune system in idiopathic nephrotic syndrome.Molecular and cellular pediatrics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical data on coronavirus disease-19 (COVID-19) in children during the management of nephrotic syndrome (NS) is lacking. Patients on prednisolone are compromised hosts at the risk of severe infections. Some infections may induce NS relapse. We describe the clinical course of a child with NS and COVID-19. A 3-year-old boy was admitted with clinical and laboratory findings indicative of NS. Induction therapy with prednisolone (2 mg/kg/day) induced complete remission. While tapering the dose, he was infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). He developed a high fever and periorbital edema. Urinalysis revealed proteinuria (protein-creatinine ratio: 6.3 g/gCr). He was transferred to our hospital for the concurrent management of COVID-19 and NS relapse. As proteinuria worsened, the prednisolone dose was increased to 2 mg/kg/day. Proteinuria gradually improved, and remission was noted a week after initiating full-dose steroid treatment. The fever subsided after 2 days without treatment for COVID-19. Anti-SARS-CoV-2 antibody including IgG levels decreased in the early convalescent phase. To the best of our knowledge, this is the first reported case with the recurrence of NS triggered by the SARS-CoV-2 infection in Asia. SARS-CoV-2 infection may induce NS relapse. Daily administration of full-dose of prednisolone may be effective for managing the recurrence of NS associated with SARS-CoV-2 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.